$CRNX insider trading
Over the last 12 months, Crinetics Pharmaceuticals insiders reported no purchases and 28 sales totaling $169.7M across SEC Form 4 filings. 57% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $169.7M 28 events
- Events · 12m
- 28 Form 4 filings, grouped
- Insiders · 12m
- 13 distinct reporters
- 10b5-1 share
- 57% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Kalofonos IsabelChief Commercial Officer · O | ▽ Sale to issuer | 35,669 | $85 | $3.0M | -100% | 2 tranches |
| Sep 1, 2026 | Betz Stephen F.Chief Scientific Officer · O | ▽ Sale to issuer | 137,936 | $85 | $11.7M | -100% | 2 tranches |
| Sep 1, 2026 | WIERENGA WENDELLD | ▽ Sale to issuer | 122,071 | $85 | $10.4M | -100% | 2 tranches |
| Sep 1, 2026 | Vivaldi Coelho RogerioD | ▽ Sale to issuer | 19,225 | $85 | $1.6M | -100% | 2 tranches |
| Sep 1, 2026 | Okey StephanieD | ▽ Sale to issuer | 12,325 | $85 | $1.0M | -100% | 2 tranches |
| Sep 1, 2026 | Nichols WestonD | ▽ Sale to issuer | 22,225 | $85 | $1.9M | -100% | 2 tranches |
| Sep 1, 2026 | Fust Matthew KD | ▽ Sale to issuer | 28,761 | $85 | $2.4M | -100% | 2 tranches |
| Sep 1, 2026 | Deardorf CarenD | ▽ Sale to issuer | 22,225 | $85 | $1.9M | -100% | 2 tranches |
| Sep 1, 2026 | Bedrosian Camille LD | ▽ Sale to issuer | 22,225 | $85 | $1.9M | -100% | 2 tranches |
| Sep 1, 2026 | Schilke TobinChief Financial & Infra. Ofcr. · O | ▽ Sale to issuer | 79,427 | $85 | $6.8M | -100% | 2 tranches |
| Sep 1, 2026 | Struthers Richard ScottPresident & CEO · O·D | ▽ Sale to issuer | 978,205 | $85 | $83.1M | -100% | 10 tranches · indirect |
| Sep 1, 2026 | Struthers Richard ScottPresident & CEO · O·D | ▽ Sale to issuer | 424,706 | $85 | $36.1M | -100% | 2 tranches |
| Jul 2, 2026 | Vivaldi Coelho RogerioD | ▼ Sale | 3,000 | $40 | $120K | -13.5% | plan |
| Jun 17, 2026 | Okey StephanieD | ▼ Sale | 6,900 | $35.67 | $246K | -51.9% | plan · 2 tranches |
| Apr 8, 2026 | Knight Jeff E.Chief Dev. & Operating Officer · O | ▼ Sale | 85,163 | $40.1 | $3.4M | -44.7% | plan |
| Mar 16, 2026 | Knight Jeff E.Chief Operating Officer · O | ▼ Sale | 9,911 | $37.37 | $370K | -8.1% | plan · 2 tranches |
| Mar 16, 2026 | Betz Stephen F.Chief Scientific Officer · O | ▼ Sale | 10,612 | $37.37 | $397K | -7.2% | plan · 2 tranches |
| Mar 16, 2026 | Struthers Richard ScottPresident & CEO · O·D | ▼ Sale | 21,981 | $37.37 | $822K | -5.2% | plan · 2 tranches |
| Mar 12, 2026 | Vivaldi Coelho RogerioD | ▼ Sale | 5,000 | $36.15 | $181K | -23.5% | plan · 2 tranches |
| Mar 3, 2026 | Okey StephanieD | ▼ Sale | 3,000 | $39.67 | $119K | -18.4% | plan |
| Mar 3, 2026 | Schilke TobinChief Financial Officer · O | ▼ Sale | 6,713 | $39.67 | $266K | -7.9% | plan |
| Jan 5, 2026 | Kalofonos IsabelChief Commercial Officer · O | ▼ Sale | 2,500 | $55 | $138K | -75% | plan |
| Dec 1, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 5,000 | $45.02 | $225K | -7% | plan |
| Nov 3, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 5,000 | $42.66 | $213K | -7% | plan · 2 tranches |
| Oct 1, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 5,000 | $41.81 | $209K | -7% | plan |
| Sep 26, 2025 | Struthers Richard ScottPresident & CEO · O·D | ▼ Sale | 4,000 | $45 | $180K | -3.6% | plan · indirect |
| Sep 26, 2025 | Fust Matthew KD | ▼ Sale | 16,000 | $44.75 | $716K | -41.2% | plan |
| Sep 2, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 5,000 | $32.1 | $161K | -4.9% | plan |
| Aug 22, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 30,000 | $30.43 | $913K | -31.2% | plan |
| Aug 20, 2025 | Pizzuti DanaChief Med and Dev Officer · O | ▼ Sale | 6,492 | $29.18 | $189K | -8.9% | plan |
Every $CRNX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Crinetics Pharmaceuticals filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CRNX feed.